Market closed
Perspective Therapeutics/$CATX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Perspective Therapeutics
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
Ticker
$CATX
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
118
CATX Metrics
BasicAdvanced
$185M
-
-$1.19
1.47
-
Price and volume
Market cap
$185M
Beta
1.47
52-week high
$19.05
52-week low
$2.36
Average daily volume
867K
Financial strength
Current ratio
9.6
Quick ratio
9.525
Long term debt to equity
1.009
Total debt to equity
1.299
Interest coverage (TTM)
-391.84%
Management effectiveness
Return on assets (TTM)
-14.35%
Return on equity (TTM)
-27.02%
Valuation
Price to revenue (TTM)
94.232
Price to book
0.56
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-3.615
Growth
Revenue change (TTM)
-351.13%
Earnings per share change (TTM)
10.16%
What the Analysts think about CATX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Perspective Therapeutics stock.
CATX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CATX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CATX News
AllArticlesVideos
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
GlobeNewsWire·4 days ago
Perspective Therapeutics to Participate in Upcoming February Investor Conferences
GlobeNewsWire·3 weeks ago
![Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fx%2F7%2Fx%2Fpress19-2870240.jpg&w=3840&q=75)
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Perspective Therapeutics stock?
Perspective Therapeutics (CATX) has a market cap of $185M as of February 25, 2025.
What is the P/E ratio for Perspective Therapeutics stock?
The price to earnings (P/E) ratio for Perspective Therapeutics (CATX) stock is 0 as of February 25, 2025.
Does Perspective Therapeutics stock pay dividends?
No, Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders as of February 25, 2025.
When is the next Perspective Therapeutics dividend payment date?
Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders.
What is the beta indicator for Perspective Therapeutics?
Perspective Therapeutics (CATX) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.